[A21-76] Ivacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book
Last updated 01.09.2021
Commission awarded on 27.05.2021 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Patients with cystic fibrosis aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have a mutation on the second allele that is not an MF, gating or RF mutation or in whom the mutation on the second allele is unknown
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.